Eberhard Ritz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eberhard Ritz has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
Nadezda Koleganova
Division of Nephrology, Department of Internal Medicine, University of Heidelberg, Im Neuenheimer Feld 162, Heidelberg 69100, Germany
7 shared publicationsRalf Dikow
Ruperto‐Carola University, Heidelberg, Germany
7 shared publicationsChristoph Wanner
Klinikum der Universität Heidelberg – Sektion Nephrologie FRCP (London und Edinburgh) FACP, Heidelberg, Germany
6 shared publicationsMartin Zeier
Ruperto-Carola University
4 shared publicationsVedat Schwenger
3 shared publicationsAndreas Tomaschitz
Department of Cardiology, Medical University Graz, Graz, Austria Specialist Clinic for Rehabilitation PV Bad Aussee, Bad Aussee, Austria
2 shared publications
Latest Publications
- Open Access
- 30 September 2016
- Published by Springer Nature in BMC Nephrology
- Vol. 17 (1) , 1-8
The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials
The orally administered spherical carbon adsorbent AST-120 is used on-label in Asian countries to slow renal disease progression in patients with progressive chronic kidney disease (CKD). Recently, two multinational, randomized, double-blind, placebo-controlled, phase 3 trials (Evaluating Prevention of Progression in Chronic Kidney Disease [EPPIC] trials) examined AST-120’s efficacy in slowing CKD progression. This study assessed the efficacy of AST-120 in the subgroup of patients from the United States of America (USA) in the EPPIC trials. In the EPPIC trials, 2035 patients with moderate to severe CKD were studied, of which 583 were from the USA. The patients were randomly assigned to two groups of equal size that were treated with AST-120 or placebo (9 g/day). The primary end point was a composite of dialysis initiation, kidney transplantation, or serum creatinine doubling. The Kaplan-Meier curve for the time to achieve the primary end point in the placebo-treated patients from the USA was similar to that projected before the study. The per protocol subgroup analysis of the population from the USA which included patients with compliance rates of ≥67 % revealed a significant difference between the treatment groups in the time to achieve the primary end point (Hazard Ratio, 0.74; 95 % Confidence Interval, 0.56–0.97). This post hoc subgroup analysis of EPPIC study data suggests that treatment with AST-120 might delay the time to primary end point in CKD patients from the USA. A further randomized controlled trial in progressive CKD patients in the USA is necessary to confirm the beneficial effect of adding AST-120 to standard therapy regimens. ClinicalTrials.gov NCT00500682 ; NCT00501046 .
- 30 September 2016
- Published by Springer Nature in BMC Nephrology
- Vol. 17 (1) , 1-8
Open AccessThe effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials
The orally administered spherical carbon adsorbent AST-120 is used on-label in Asian countries to slow renal disease progression in patients with progressive chronic kidney disease (CKD). Recently, two multinational, randomized, double-blind, placebo-controlled, phase 3 trials (Evaluating Prevention of Progression in Chronic Kidney Disease [EPPIC] trials) examined AST-120’s efficacy in slowing CKD progression. This study assessed the efficacy of AST-120 in the subgroup of patients from the United States of America (USA) in the EPPIC trials. In the EPPIC trials, 2035 patients with moderate to severe CKD were studied, of which 583 were from the USA. The patients were randomly assigned to two groups of equal size that were treated with AST-120 or placebo (9 g/day). The primary end point was a composite of dialysis initiation, kidney transplantation, or serum creatinine doubling. The Kaplan-Meier curve for the time to achieve the primary end point in the placebo-treated patients from the USA was similar to that projected before the study. The per protocol subgroup analysis of the population from the USA which included patients with compliance rates of ≥67 % revealed a significant difference between the treatment groups in the time to achieve the primary end point (Hazard Ratio, 0.74; 95 % Confidence Interval, 0.56–0.97). This post hoc subgroup analysis of EPPIC study data suggests that treatment with AST-120 might delay the time to primary end point in CKD patients from the USA. A further randomized controlled trial in progressive CKD patients in the USA is necessary to confirm the beneficial effect of adding AST-120 to standard therapy regimens. ClinicalTrials.gov NCT00500682 ; NCT00501046 .
- 1 June 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 43 (06) , 250-254
Die Rolle von Aldosteron bei Nierenkrankheiten
- 1 June 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 43 (06) , 250-254
Die Rolle von Aldosteron bei Nierenkrankheiten
- Open Access
- 27 November 2013
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 6 (6) , 674
Mineralocorticoid receptor blockade--a novel approach to fight hyperkalaemia in chronic kidney disease
Clin Kidney J (2013); 6:464–468. doi:10.1093/ckj/sft084
- 27 November 2013
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 6 (6) , 674
Open AccessMineralocorticoid receptor blockade--a novel approach to fight hyperkalaemia in chronic kidney disease
Clin Kidney J (2013); 6:464–468. doi:10.1093/ckj/sft084
- Open Access
- 4 November 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 29 (11) , 2012-2019
Aldosterone and the kidney: a rapidly moving frontier (an update)
Beyond the classical effect of aldosterone on sodium reabsorption in the distal nephron, the spectrum of aldosterone-induced effects on the kidney (and the cardiovascular system) continues to expand at a rapid pace. Blockade of this system has become an attractive target for intervention. Major contributions have been reported in the past 2–3 years. By necessity this brief summary addresses only some of the emerging issues of nephrological relevance. In this fast moving field, we try to give a concise discussion of papers with potential nephrological relevance in the past 2–3 years.
- 4 November 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 29 (11) , 2012-2019
Open AccessAldosterone and the kidney: a rapidly moving frontier (an update)
Beyond the classical effect of aldosterone on sodium reabsorption in the distal nephron, the spectrum of aldosterone-induced effects on the kidney (and the cardiovascular system) continues to expand at a rapid pace. Blockade of this system has become an attractive target for intervention. Major contributions have been reported in the past 2–3 years. By necessity this brief summary addresses only some of the emerging issues of nephrological relevance. In this fast moving field, we try to give a concise discussion of papers with potential nephrological relevance in the past 2–3 years.
- Open Access
- 1 September 2013
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 6 (5) , 464-468
Mineralocorticoid receptor blockade--a novel approach to fight hyperkalaemia in chronic kidney disease
Hyperkalaemia continues to be a major hazard of mineralocorticoid receptor blockade in an effort to retard the progression of chronic kidney disease (CKD). In cardiac patients on mineralocorticoid receptor blockade, RLY-5016 which captures K+ in the colon has been effective in reducing the risk of hyperkalaemia. This compound might be useful in CKD as well.
- 1 September 2013
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 6 (5) , 464-468
Open AccessMineralocorticoid receptor blockade--a novel approach to fight hyperkalaemia in chronic kidney disease
Hyperkalaemia continues to be a major hazard of mineralocorticoid receptor blockade in an effort to retard the progression of chronic kidney disease (CKD). In cardiac patients on mineralocorticoid receptor blockade, RLY-5016 which captures K+ in the colon has been effective in reducing the risk of hyperkalaemia. This compound might be useful in CKD as well.
- Open Access
- 12 December 2012
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 6 (4) , 368-372
Bariatric surgery and the kidney—much benefit, but also potential harm
Bariatric surgery is increasingly performed on overweight individuals. A significant benefit with respect to cardiovascular (CV) events and survival has been documented. After weight loss, reduction of albuminuria/proteinuria is almost consistently seen; small studies documented retardation of the glomerular filtration rate (GFR) loss after bariatric surgery; reduction of blood pressure (BP) is less consistent. It has been known for a long time that the frequency of oxalate stones is increased after bariatric surgery. The main renal threat of hyperoxaluria is renal oxalosis, often irreversible, causing persisting renal failure. The causes are reduced oxalate binding by calcium due to saponification of calcium causing fat malabsorption, increased permeability for oxalate because of increased permeability of colon mucosa triggered by increased bile salts and reduced colonization of the colon by oxalobacter formigenes. These mechanisms are susceptible to treatment.
- 12 December 2012
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 6 (4) , 368-372
Open AccessBariatric surgery and the kidney—much benefit, but also potential harm
Bariatric surgery is increasingly performed on overweight individuals. A significant benefit with respect to cardiovascular (CV) events and survival has been documented. After weight loss, reduction of albuminuria/proteinuria is almost consistently seen; small studies documented retardation of the glomerular filtration rate (GFR) loss after bariatric surgery; reduction of blood pressure (BP) is less consistent. It has been known for a long time that the frequency of oxalate stones is increased after bariatric surgery. The main renal threat of hyperoxaluria is renal oxalosis, often irreversible, causing persisting renal failure. The causes are reduced oxalate binding by calcium due to saponification of calcium causing fat malabsorption, increased permeability for oxalate because of increased permeability of colon mucosa triggered by increased bile salts and reduced colonization of the colon by oxalobacter formigenes. These mechanisms are susceptible to treatment.
- Open Access
- 1 December 2012
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (suppl 4) , iv28-iv30
Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study
It is plausible to assume that the earlier the stage of diabetic nephropathy the greater is the chance of successful intervention; this is suggested e.g. by the observation of Siragy and Carey [1], who report that in diabetic nephropathy the efficacy of delayed RAS blockade is limited. In the past, it had commonly been assumed that kidney disease in diabetes starts with an increase in albuminuria and progresses to the stages of microalbuminuria and subsequently to overt proteinuria and progressive loss of renal function. Although recent observations indicate that this is not true in all cases of type 2 [2, 3] or type 1 [4] diabetes, this scheme is certainly valid in the majority of patients. The urinary albumin excretion in diabetes constitutes a continuum so that the diagnosis of microalbuminuria is somewhat arbitrary––which led to the proposal to abandon the concept of microalbuminuria [5], because in type 2 diabetics renal and cardiovascular (CV) risks increase progressively with increasing albumin excretion even within the normal range [6]. Nevertheless, the onset of microalbuminuria remains [1] a valid parameter for intervention studies.
- 1 December 2012
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (suppl 4) , iv28-iv30
Open AccessPrevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study
It is plausible to assume that the earlier the stage of diabetic nephropathy the greater is the chance of successful intervention; this is suggested e.g. by the observation of Siragy and Carey [1], who report that in diabetic nephropathy the efficacy of delayed RAS blockade is limited. In the past, it had commonly been assumed that kidney disease in diabetes starts with an increase in albuminuria and progresses to the stages of microalbuminuria and subsequently to overt proteinuria and progressive loss of renal function. Although recent observations indicate that this is not true in all cases of type 2 [2, 3] or type 1 [4] diabetes, this scheme is certainly valid in the majority of patients. The urinary albumin excretion in diabetes constitutes a continuum so that the diagnosis of microalbuminuria is somewhat arbitrary––which led to the proposal to abandon the concept of microalbuminuria [5], because in type 2 diabetics renal and cardiovascular (CV) risks increase progressively with increasing albumin excretion even within the normal range [6]. Nevertheless, the onset of microalbuminuria remains [1] a valid parameter for intervention studies.
- 30 November 2012
- Published by Springer Nature in Der Nephrologe
- Vol. 8 (1) , 37-42
Phosphat und Nahrung
- 30 November 2012
- Published by Springer Nature in Der Nephrologe
- Vol. 8 (1) , 37-42
Phosphat und Nahrung
- Open Access
- 7 October 2012
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (15) , 1099-1101
Phosphate: a novel cardiovascular risk factor
It has recently been recognized that even in the normal population high normal phosphate concentrations are associated with increased all-cause and cardiovascular mortality. Organic phosphates in unprocessed food items are less efficiently absorbed than food additives in the form of inorganic phosphate salts. This is of relevance because even high normal and even more so elevated phosphate concentrations are correlated with reduced life expectancy and cardiovascular events. The underlying pathophysiology includes endothelial dysfunction, vascular calcification, and cardiac hypertrophy. Phosphate intake and serum phosphate concentrations must be considered as novel cardiovascular risk factors (although the causality of the correlation has not been definitely established).
- 7 October 2012
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (15) , 1099-1101
Open AccessPhosphate: a novel cardiovascular risk factor
It has recently been recognized that even in the normal population high normal phosphate concentrations are associated with increased all-cause and cardiovascular mortality. Organic phosphates in unprocessed food items are less efficiently absorbed than food additives in the form of inorganic phosphate salts. This is of relevance because even high normal and even more so elevated phosphate concentrations are correlated with reduced life expectancy and cardiovascular events. The underlying pathophysiology includes endothelial dysfunction, vascular calcification, and cardiac hypertrophy. Phosphate intake and serum phosphate concentrations must be considered as novel cardiovascular risk factors (although the causality of the correlation has not been definitely established).
- Open Access
- 13 September 2012
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 12 (1) , 19
Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of the mineralocorticoid receptor-blocker eplerenone to reduce parathyroid hormone secretion in patients with parathyroid hormone excess.
- 13 September 2012
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 12 (1) , 19
Open AccessEffect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of the mineralocorticoid receptor-blocker eplerenone to reduce parathyroid hormone secretion in patients with parathyroid hormone excess.